Q3 2025 Bausch Health Companies Inc Earnings Call Transcript
Key Points
- Bausch Health Companies Inc (BHC) delivered its 10th consecutive quarter of revenue and adjusted EBITDA growth, showcasing consistent strong performance.
- The company achieved a 7% year-over-year revenue growth on a reported basis and 5% on an organic basis, excluding Bausch + Lomb.
- Solta and Salix businesses experienced excellent double-digit growth, with Solta growing 25% and Salix 12% on a reported basis.
- BHC reduced its debt by approximately $600 million, demonstrating effective cash management and financial discipline.
- The company raised its full-year guidance for revenue, adjusted EBITDA, and adjusted cash flow from operations, reflecting confidence in continued strong performance.
- Adjusted gross margin decreased by 40 basis points year over year, indicating some pressure on profitability.
- The International segment saw a revenue decrease of 2% on a reported basis and 4% on an organic basis, with mixed performance across geographies.
- The diversified segment experienced a 4% decrease in revenue on a reported basis, driven by challenges in the neurology business.
- Relistor continues to face a challenging payer coverage environment, impacting its growth potential.
- The company is dealing with the impact of CMS price negotiations on Xifaxan, which could affect future revenue and profitability.
Greetings, and welcome to the Bausch Health third-quarter 2025 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded.
It's now my pleasure to turn the call over to your host, Garen Sarafian, Vice President, Investor Relations. Garen, please go ahead.
Good afternoon, and welcome to Bausch Health's third-quarter 2025 earnings conference call. Participating in today's call are Thomas Appio, Chief Executive Officer of Bausch Health; and JJ Charhon, Chief Financial Officer.
Before we begin, I would like to remind you that our presentation today contains forward-looking information. We ask you to take a moment to read the forward-looking statements disclaimer at the beginning of the pages that accompany this presentation as it contains important information. Our actual results may vary materially from those expressed or implied in our forward-looking statements, and you should not place undue reliance on any forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
